Bausch & Lomb Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1992-10-08

Employees: -

Market Cap: -

Website

Clinical Trials

Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Astigmatism by Transepithelial Photorefractive Keratectomy

Not Applicable

Not yet recruiting

Conditions: Myopia

Interventions: Device: TENEO 317 Model 2 excimer laser

First Posted Date: 2024-10-01

Last Posted Date: 2024-12-13

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 140

Registration Number: NCT06618547

A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects Undergoing Cataract Extraction

Not Applicable

Recruiting

Conditions: Cataract

Interventions: Device: enVista Aspire EA or Aspire Toric ETA IOLs

First Posted Date: 2024-09-13

Last Posted Date: 2024-09-13

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 450

Registration Number: NCT06594185

Locations: 🇺🇸
Site 118, Birmingham, Alabama, United States
🇺🇸
Site 105, Tucson, Arizona, United States
🇺🇸
Site 104, Bakersfield, California, United States

and more 17 locations

A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

Phase 4

Active, not recruiting

Conditions: Dry Eye

Interventions: Drug: Miebo
Drug: Saline

First Posted Date: 2024-08-22

Last Posted Date: 2024-12-17

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 216

Registration Number: NCT06565650

Locations: 🇺🇸
Site 101, Glendale, California, United States
🇺🇸
Site 112, Murrieta, California, United States
🇺🇸
Site 102, Newport Beach, California, United States

and more 9 locations

Clinical Evaluation of the Performance of the enVista® Aspire™ (EA) Lens

Not Applicable

Terminated

Conditions: Cataract

Interventions: Device: MX60E
Device: An IOL with a slightly extended depth of focus
Device: enVista® Aspire™

First Posted Date: 2024-06-28

Last Posted Date: 2024-12-27

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 27

Registration Number: NCT06479148

Locations: 🇭🇳
Site 101 Centro Oftalmológico Robles, Santa Rosa De Copán, Copán, Honduras

A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy

Phase 4

Active, not recruiting

Conditions: Dry Eye

Interventions: Drug: Miebo

First Posted Date: 2024-04-04

Last Posted Date: 2024-11-18

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 100

Registration Number: NCT06346340

Locations: 🇺🇸
Site 109, Sacramento, California, United States
🇺🇸
Site 111, Grand Junction, Colorado, United States
🇺🇸
Site 108, Alexandria, Minnesota, United States

and more 9 locations

A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction

Recruiting

Conditions: Cataract

Interventions: Device: enVista Aspire EA IOLs

First Posted Date: 2024-03-27

Last Posted Date: 2024-12-11

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 100

Registration Number: NCT06333028

Locations: 🇺🇸
Site 107, Cranberry Township, Pennsylvania, United States
🇺🇸
SITE 104, Dover, New Jersey, United States
🇺🇸
Site 105, Woodland Park, New Jersey, United States

and more 4 locations

Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction

Not Applicable

Recruiting

Conditions: Cataract

Interventions: Device: enVista EY Beyond IOL
Device: enVista MX60E monofocal IOL

First Posted Date: 2024-03-27

Last Posted Date: 2024-11-18

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 224

Registration Number: NCT06333015

Locations: 🇺🇸
Site 106, Sioux Falls, South Dakota, United States
🇺🇸
Site 103, Dallas, Texas, United States
🇺🇸
Site 111, Mount Pleasant, Wisconsin, United States

and more 6 locations

A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

Phase 4

Completed

Conditions: Dry Eye

Interventions: Drug: Miebo

First Posted Date: 2024-03-13

Last Posted Date: 2024-06-21

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 99

Registration Number: NCT06309953

Locations: 🇺🇸
Site 203, Pittsburg, Kansas, United States
🇺🇸
Site 202, Kansas City, Missouri, United States
🇺🇸
Site 204, Stillwater, Minnesota, United States

and more 2 locations

A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children

Not Applicable

Recruiting

Conditions: Myopia

Interventions: Device: Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)
Device: CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens

First Posted Date: 2024-03-12

Last Posted Date: 2024-05-23

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 418

Registration Number: NCT06305663

Locations: 🇨🇳
Site 103, Chengdu, Sichaun Province, China
🇨🇳
Site 110, Wuhan, Hubei, China
🇨🇳
Site 105, Beijing, Beijing, China

and more 8 locations

Kalifilcon A Toric Compared to Commercially Available Lenses

Not Applicable

Completed

Conditions: Astigmatism

Interventions: Device: Precision1 for Astigmatism
Device: Kalifilcon Toric Lens
Device: MyDay Toric
Device: Total1 for Astigmatism

First Posted Date: 2023-10-25

Last Posted Date: 2024-12-10

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 30

Registration Number: NCT06098937

Locations: 🇺🇸
Bausch & Lomb, Incorporated, Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy